Marinus Q2 update

 

• ZTALMY® (ganaxolone) second quarter net product revenue of $4.2 million; 2023 net product revenue guidance increased to between $17 and $18.5 million

• European Commission approved ZTALMY in CDKL5 deficiency disorder

• Interim analysis for the Phase 3 refractory status epilepticus trial now expected Q1 2024

• First patient dosed in MAD trial with second generation ganaxolone formulation

• New emergency IND dosing paradigm for super refractory status epilepticus showing encouraging initial results

• Granted a new method of use patent by USPTO for ganaxolone in tuberous sclerosis complex

• Cash runway expected into second half of 2024 with cash, cash equivalents and short-term investments of $175.3 million as of June 30, 2023

• Marinus to host conference call on August 10, 2023, at 8:30 a.m. ET

Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

https://finance.yahoo.com/news/marinus-pharmaceuticals-provides-business-reports-110100923.html